Gregory P. Pogue
Nessuna posizione attualmente
Profilo
Dr. Gregory P.
Pogue is Vice President-Business Development at Emergent Technologies, Inc., President at Receptor Logic Ltd., Chief Scientist at Pure Protein LLC, and President & Managing Director at MHC Biologics LLC.
Dr. Pogue holds a B.S.
from Midwestern State University and a Ph.D.
from Texas A&M University.
Precedenti posizioni note di Gregory P. Pogue
Società | Posizione | Fine |
---|---|---|
MHC Biologics LLC
MHC Biologics LLC BiotechnologyHealth Technology MHC Biologics, LLC, an emerging biotechnology company, has developed a unique and proprietary portfolio of breakthrough technologies that can be used in the development and design of novel therapeutics, including therapeutic vaccines for cancer and other diseases. MHC Biologics has been founded to focus on clinical applications of a suite of immunology tools developed in the laboratories of Dr. Jon Weidanz, Texas Tech University Pharmacy School and Receptor Logic, Ltd., and Dr. William Hildebrand, Oklahoma University Health Science Center and Pure Vaccine Solutions, LLC. These technology 'tools' can be utilized for immunology-based cancer diagnosis and treatment. Funded and managed by life sciences venture firm, Emergent Technologies, Inc., MHC Biologics is actively seeking commercialization partners. MHC Biologics offers breakthrough therapeutic antibody technology targeting a new class of disease biomarkers - peptides presented by the Major Histocompatibility Complex (MHC; also known as human leukocyte antigen, or HLA). These peptides are derived from intracellular processing of tumor or viral proteins and are presented as complexes with MHC proteins on antigen-presenting cells. MHC Biologics' unique antibody strategy exhibits disease-specific binding and efficacy in preclinical studies as a cancer therapeutic modality, providing next-generation products for treatment of cancer and other important diseases. | Presidente | 07/02/2013 |
Emergent Technologies, Inc.
Emergent Technologies, Inc. Investment ManagersFinance Emergent Technologies, Inc. (Emergent Technologies) is a venture capital firm founded in 1989 by Thomas A. Harlan. The firm is headquartered in Austin. Texas. | Corporate Officer/Principal | 31/05/2011 |
Pure Protein LLC
Pure Protein LLC Pharmaceuticals: MajorHealth Technology Pure Protein LLC specializes in immunology tools for diagnostics, drug and vaccine development, and high-yield protein production. It operates as a biopharmaceutical company, produces soluble human leukocyte antigen (sHLA) proteins and custom products in various human and animal cell lines. The firm provides sHLA class I and II proteins for use in transplantation, drug target discovery, and bio-therapeutic development, as well as diagnostic and therapeutic reagents for use in immunology research and development. The company was founded by William Hildebrand in 1999 and is headquartered in Austin, TX. | Direttore Tecnico/Scientifico/R&S | - |
Receptor Logic, Inc.
Receptor Logic, Inc. Pharmaceuticals: MajorHealth Technology Receptor Logic, Inc. provides a novel solution for the treatment of infectious diseases and cancers. The company was founded by Jon Weidanz in 2003 and is headquartered in Austin, TX. | Presidente | - |
Formazione di Gregory P. Pogue
Texas A&M University | Doctorate Degree |
Midwestern State University (Texas) | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 4 |
---|---|
Emergent Technologies, Inc.
Emergent Technologies, Inc. Investment ManagersFinance Emergent Technologies, Inc. (Emergent Technologies) is a venture capital firm founded in 1989 by Thomas A. Harlan. The firm is headquartered in Austin. Texas. | Finance |
Receptor Logic, Inc.
Receptor Logic, Inc. Pharmaceuticals: MajorHealth Technology Receptor Logic, Inc. provides a novel solution for the treatment of infectious diseases and cancers. The company was founded by Jon Weidanz in 2003 and is headquartered in Austin, TX. | Health Technology |
Pure Protein LLC
Pure Protein LLC Pharmaceuticals: MajorHealth Technology Pure Protein LLC specializes in immunology tools for diagnostics, drug and vaccine development, and high-yield protein production. It operates as a biopharmaceutical company, produces soluble human leukocyte antigen (sHLA) proteins and custom products in various human and animal cell lines. The firm provides sHLA class I and II proteins for use in transplantation, drug target discovery, and bio-therapeutic development, as well as diagnostic and therapeutic reagents for use in immunology research and development. The company was founded by William Hildebrand in 1999 and is headquartered in Austin, TX. | Health Technology |
MHC Biologics LLC
MHC Biologics LLC BiotechnologyHealth Technology MHC Biologics, LLC, an emerging biotechnology company, has developed a unique and proprietary portfolio of breakthrough technologies that can be used in the development and design of novel therapeutics, including therapeutic vaccines for cancer and other diseases. MHC Biologics has been founded to focus on clinical applications of a suite of immunology tools developed in the laboratories of Dr. Jon Weidanz, Texas Tech University Pharmacy School and Receptor Logic, Ltd., and Dr. William Hildebrand, Oklahoma University Health Science Center and Pure Vaccine Solutions, LLC. These technology 'tools' can be utilized for immunology-based cancer diagnosis and treatment. Funded and managed by life sciences venture firm, Emergent Technologies, Inc., MHC Biologics is actively seeking commercialization partners. MHC Biologics offers breakthrough therapeutic antibody technology targeting a new class of disease biomarkers - peptides presented by the Major Histocompatibility Complex (MHC; also known as human leukocyte antigen, or HLA). These peptides are derived from intracellular processing of tumor or viral proteins and are presented as complexes with MHC proteins on antigen-presenting cells. MHC Biologics' unique antibody strategy exhibits disease-specific binding and efficacy in preclinical studies as a cancer therapeutic modality, providing next-generation products for treatment of cancer and other important diseases. | Health Technology |
- Borsa valori
- Insiders
- Gregory P. Pogue